Amicus Therapeutics Inc (FRA:AM6)
€ 9.3 0.2 (2.2%) Market Cap: 2.82 Bil Enterprise Value: 3.01 Bil PE Ratio: 0 PB Ratio: 16.43 GF Score: 78/100

Amicus Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 08:00PM GMT
Release Date Price: €10.64 (-2.92%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Thanks for joining us here at Bank of America Merrill Lynch Conference. I am Tazeen Ahmad, the senior SMid biotech analyst here. Our next presenting company is Amicus Therapeutics. Sitting next to me from Amicus is Brad Campbell, Chief Operating Officer and President. We also have a couple of members of the management team in the audience today as well.

So thank you, Brad, for coming and presenting. For those people who aren't as familiar with the details of Amicus, maybe you can spend a couple of minutes just telling us about the company, your commercial products so far and maybe just a summary of what you've got going on in the pipeline?

Bradley L. Campbell
Amicus Therapeutics, Inc. - President, COO & Director

Sure. Yes. First, thanks, Tazeen, for having us here, and thanks to Bank of America Merrill Lynch for hosting us. Always a great conference for us every year. So we really appreciate the time.

For those of you who aren't totally familiar, Amicus Therapeutics is a global

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot